Korea Hanmei group (hereinafter referred to as the Han Mei Group) was founded by Mr. Lin Shengji in 1973, the headquarters is located in Seoul of korea. It is adhering to the people-oriented business philosophy, value creation, committed to the development of prescription drugs, has more than 280 kinds of patent technology, in the leading position in the cardiovascular, digestive, antibiotic, antitumor, pediatric etc.. Provide 200 kinds of drugs for clinical treatment to global, Roche, Novartis and other international well-known pharmaceutical manufacturers sell patent, transfer of technology, with its world leading science and technology, advanced equipment, the curative effect of drugs, to become a world famous pharmaceutical experts. It also has fine chemicals, Hing Institute of antibiotics, Pyeongtaek factory, Medicare subsidiaries, laid a solid foundation of its R & D, production and sales, and through the China, Japan, countries such as the UK subsidiary, become an international professional pharmaceutical enterprises.
Han Mei group with long-term protein / polypeptide medicine technology (LAPSCOVERY) and oral pharmaceutical technology (ORASCOVERY) two high-quality R & D technology as the core, the research and development of the Korean domestic drug products. The company has antibiotic, heart disease, digestive, anti-tumor and other areas of two hundred kinds of excellent products.
Korean American group received numerous honors in the development process, including best business award, South Korea's most trusted enterprise award, best employer, Forbes outstanding management award, best CEO, Korea Medicine Research Association (KDRA) the best drug research award, the South Korean Ministry of knowledge economy (MKE) and South Korea (Bureau of technical progress KIAT) new technology prize, awarded the excellent Korean technology award.
Han Mei Group for decades, through the continuous development, the company scale and sales to maintain strong growth, has made great contribution to the global field of medicine. Han Mei Group in South Korea this department, also have drug research center and a number of production bases, overseas institutions all over China, Japan, Europe and other countries and regions. Han Mei Group visions of the future is the 2015 overseas sales topped $1000000000 in 2020, overseas sales reached 3000000000.
